ESMO 2019 | Melanoma musings: Dr Ascierto’s trial updates from ESMO

Paolo Ascierto

Paolo Ascierto, MD, National Tumor Institute, Milan, Italy, examines and explains the key melanoma updates from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. Dr Ascierto touches on various combination therapies, including ipilimumab and nivolumab in the treatment of stage IV, high-risk melanoma patients and the triplet combination of dabrafenib, trametinib, and pembrolizumab.

Share this video